The Biden administration released the negotiated prices for the first ten prescription drugs subject to Medicare negotiations with drug companies. The new negotiated prices are expected to save Medicare $6 billion in costs in 2026 alone. Some of the drugs are taken for heart conditions, diabetes, and kidney failure. The negotiations aim to make costly medications more affordable for older Americans and achieve significant savings for Medicare and patients. The pharmaceutical industry opposes the negotiations, arguing it will reduce drug company profits and limit innovation. Several lawsuits have been filed to stop the process.
